(Q37352050)

19 August 2017

title

What's in the pipeline for the treatment of Parkinson's disease? (English)

1 reference

19 August 2017

1 reference

David B Sommer

1

1 reference

19 August 2017

Mark A Stacy

series ordinal

2

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

1829-1839

1 reference

Future directions in the treatment of Parkinson's disease

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Treatment of Parkinson's disease : what's on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Dopamine agonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Targeting adenosine A2A receptors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Glutamate receptors and Parkinson's disease: opportunities for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Protection against Parkinson's disease progression: clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson's patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Vitamin D and Parkinson's disease--a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Treatment of Parkinson's disease with trophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Recent advances in cell-based therapy for Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Does transcranial magnetic stimulation improve the motor symptoms of Parkinson disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Placebo-controlled study of rTMS for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Motor cortex stimulation for pain and movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Dementia and survival in Parkinson disease: a 12-year population study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.12.1829

10.1586/14737175.8.12.1829

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference